# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Morgan Stanley analyst Sean Laaman maintains Exelixis (NASDAQ:EXEL) with a Overweight and raises the price target from $46 t...
Goldman Sachs analyst Paul Choi initiates coverage on Exelixis (NASDAQ:EXEL) with a Buy rating and announces Price Target of...
HC Wainwright & Co. analyst Robert Burns maintains Exelixis (NASDAQ:EXEL) with a Buy and lowers the price target from $5...
Ten large-cap stocks, including Novo Nordisk and UPS, tumbled last week on weak earnings and guidance cuts.